SOURCE: NeuroPerspective

NeuroPerspective

December 05, 2011 10:48 ET

Depression Therapeutics Reviewed by NeuroPerspective

CARDIFF, CA--(Marketwire - Dec 5, 2011) - NeuroPerspective has released its December issue, which reviews the field of therapeutics for depression. The treatment of depression, while a major success story for psychopharmacology, has been far from ideal, given the high percentage of patients who are treatment-refractory or who experience significant side effects. Depression remains an undertreated disorder of enormous magnitude and societal cost. With patent protection evaporating for major antidepressant brands, the depression market has become one that is dominated by generics.

However, there are programmatic developments in the depression area which may allow the pharma industry to regain momentum by producing products whose advantages could make them highly useful for the majority of patients who do not achieve adequate symptom relief with their first trial of a generic. These developments include:

1) While Targacept and Astra Zeneca recently announced negative results from their first Phase III trial for the nicotinic adjunct TC-5214 adjunct, this was in stark contrast to their impressive Phase IIb results. All attention is now focused on the next three Phase III trials, reporting over the first half of 2012.

2) Naurex's GlyX-13 is completing its first Phase II trial, seeking to establish its ability to safely emulate ketamine's rapid relief of depression symptoms. This is the vanguard of several glutamatergic approaches to depression, including mGluR (Roche, BrainCells) and NR2B (Evotec) tactics.

3) Selective MAO inhibition has been an option in Europe for TRD, but not in the US. CeNeRx is completing a very well-executed Phase IIb trial for its MAO-A inhibitor, TriRima, results due by mid-2012.

4) Triple-amine inhibitors continue in advanced clinical development by Takeda/Lundbeck and Euthymics Bioscience.

The December issue also includes more detailed looks at: the first Phase III failure for TC-5214, in the context of the depression field's highly inconsistent record in pivotal testing; a pointed comment on Geron's decision to exit the stem cell field when the clinical utility of the approach was finally being tested in spinal cord injury; and the not-so-hidden costs of hastened enrollment in conducting clinical trials ('Speed Kills').

NeuroPerspective is the independent, monthly review of the neurotherapeutics area. A one-year subscription is US$2200, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month trial subscription is US$700. The December issue is being made available as a single-issue purchase for US$400.

NI Research is the leading publisher of independent research on the neuropharmaceutical/therapeutic industry. NI Research has published NeuroPerspective (formerly NeuroInvestment) since 1995; the Private CNS Company Review since 2003; and CNS Therapeutics and Licensing, an annual compendium of all CNS R&D programs, since 2007. NI Research has developed an unmatched information base regarding both publicly and privately held neurotherapeutics companies, and offers M&A/licensing consultation services.

Contact Information